GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (FRA:THR) » Definitions » EV-to-EBIT

ThermoGenesis Holdings (FRA:THR) EV-to-EBIT : -0.80 (As of May. 17, 2024)


View and export this data going back to 2007. Start your Free Trial

What is ThermoGenesis Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ThermoGenesis Holdings's Enterprise Value is €6.56 Mil. ThermoGenesis Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.22 Mil. Therefore, ThermoGenesis Holdings's EV-to-EBIT for today is -0.80.

The historical rank and industry rank for ThermoGenesis Holdings's EV-to-EBIT or its related term are showing as below:

FRA:THR' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.72   Med: -1.89   Max: -0.05
Current: -1.43

During the past 13 years, the highest EV-to-EBIT of ThermoGenesis Holdings was -0.05. The lowest was -7.72. And the median was -1.89.

FRA:THR's EV-to-EBIT is ranked worse than
100% of 460 companies
in the Medical Devices & Instruments industry
Industry Median: 20.385 vs FRA:THR: -1.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. ThermoGenesis Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was €0.00 Mil. ThermoGenesis Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-8.22 Mil. ThermoGenesis Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.


ThermoGenesis Holdings EV-to-EBIT Historical Data

The historical data trend for ThermoGenesis Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings EV-to-EBIT Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.77 -2.16 -2.56 -1.38 -0.99

ThermoGenesis Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.38 -1.19 -1.21 -1.19 -0.99

Competitive Comparison of ThermoGenesis Holdings's EV-to-EBIT

For the Medical Devices subindustry, ThermoGenesis Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's EV-to-EBIT falls into.



ThermoGenesis Holdings EV-to-EBIT Calculation

ThermoGenesis Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=6.563/-8.215
=-0.80

ThermoGenesis Holdings's current Enterprise Value is €6.56 Mil.
ThermoGenesis Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings  (FRA:THR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

ThermoGenesis Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-8.215/0
= %

ThermoGenesis Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was €0.00 Mil.
ThermoGenesis Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (FRA:THR) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.